Q4 2025 Earnings Call March 5, 2026 4:30 PM ESTCompany ParticipantsStephen Silvestro - President & CEOEdward Stelmakh ...
Founder, who will provide a business update and an overview of our clinical and operational progress. Rita Johnson Green, our ...
The only approved gene therapy for RP today targets a single gene RPE65, which accounts for just 1% to 2% of the total RP patient population. We believe OCU400 has significantly wider commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results